Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Strattera (1)

2C-x series (1) · Phenethylamine (1) · Psychedelic (1) · [[:Category:ADHD medicines|ADHD medicine]] (1) · [[:Category:NRIs|Selective norepinephrine reuptake inhibitor (NRI)]] (1)

None (1) · 5-HT2A partial agonist (1)

None (1) · '"`UNIQ--vote-00000013-QINU`"' (1)

None (1) · Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks (1)

None (1) · Capsules 10, 18, 25, 40, 60, 80, 100 mg (1)

None (1) · 100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower) (1)

insufflated (1) · Oral (2) · PR (1)

45-75 min (oral) (1) · ADHD effect emerges over 1-2 weeks (slower than psychostimulants); full effect 4-6 weeks (1)

24 hours (once-daily or split BID dosing) (1) · 4-8 h (1)

Not well characterized (1) · ~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers'"`UNIQ--ref-00000014-QINU`"' (1)

Not well characterized (1) · ~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"' (1)

Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)

[[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US. '''Not a controlled substance''', the principal clinical selling point versus psychostimulant ADHD options. Carries the antidepressant-class '''Boxed Warning''' for suicidal ideation in pediatric patients'"`UNIQ--ref-00000016-QINU`"' (1)